Evidence map›Paper›PMID 42545411›Full record

Trial reportAnnals of surgical oncology2026

Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.

J Tseng, K Dimitroff, C A M Sauder, A J Chien, K A Ahmed, L F Allen, C A Arciero, E E Burke, J M Chandler, J E Jordan and 33 more

Erratum issued Registry-linked trialAbstract readClinical Trial, Phase IIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01042379 (I-SPY Trial), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01042379 phase2recruitingnot on this map

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

TypeinterventionalSponsorQuantumLeap Healthcare CollaborativeRan2010 to 2031Enrolled5,000ConditionsBreast Neoplasms, Breast Cancer, Breast Tumors, AngiosarcomaArmsStandard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

43 authors.

J TsengCity of Hope Comprehensive Cancer Center, Irvine, CA, USA. jetseng@coh.org.ORCID http://orcid.org/0000-0002-9124-8153
K DimitroffQuantum Leap Healthcare Collaborative, San Francisco, CA, USA.
C A M SauderUniversity of California Davis, Sacramento, CA, USA.
A J ChienUniversity of California San Francisco, San Francisco, CA, USA.
K A AhmedH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
L F AllenAtrium Health Wake Forest Baptist, Winston-Salem, NC, USA.
C A ArcieroEmory University, Atlanta, GA, USA.
E E BurkeThe Ohio State University Health System, Columbus, OH, USA.
J M ChandlerUniversity of California San Francisco, San Francisco, CA, USA.
J E JordanUniversity of California San Francisco, San Francisco, CA, USA.
M GolshanYale University School of Medicine, New Haven, CT, USA.
L A GutnikUniversity of Alabama at Birmingham, Birmingham, AL, USA.
N T JaskowiakThe University of Chicago Medicine, Chicago, IL, USA.
K C HewittUniversity of Utah Health, Salt Lake City, UT, USA.
M Howard-McNattAtrium Health Wake Forest Baptist, Winston-Salem, NC, USA.
F ItoUniversity of Southern California, Los Angeles, CA, USA.
I M KangCity of Hope Comprehensive Cancer Center, Irvine, CA, USA.
S B KesmodelUniversity of Miami Hospital, Miami, FL, USA.
H M KuererUT MD Anderson Cancer Center, Houston, TX, USA.
M C LeeH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
M S MoranYale University School of Medicine, New Haven, CT, USA.
L M PostlewaitEmory University, Atlanta, GA, USA.
N D PrionasUniversity of California San Francisco, San Francisco, CA, USA.
R RaoColumbia University Medical Center, New York, NY, USA.
C R ReynaLoyola University Medical Center, Maywood, IL, USA.
A SchwerCity of Hope Comprehensive Cancer Center, Irvine, CA, USA.
N K TaunkUniversity of Pennsylvania, Philadelphia, PA, USA.
J TchouUniversity of Pennsylvania, Philadelphia, PA, USA.
A M WallaceUniversity of California San Diego, San Diego, CA, USA.
T J LiUniversity of California San Francisco, San Francisco, CA, USA.
J PerlmutterGemini Group Consultancy, St. Louis, MO, USA.
A M DeMicheleUniversity of Pennsylvania, Philadelphia, PA, USA.
D YeeUniversity of Minnesota, Minneapolis, MN, USA.
N M HyltonUniversity of California San Francisco, San Francisco, CA, USA.
L J Van't VeerUniversity of California San Francisco, San Francisco, CA, USA.
H S RugoCity of Hope Comprehensive Cancer Center, Duarte, CA, USA.
W F SymmansUT MD Anderson Cancer Center, Houston, TX, USA.
R A ShatskyUniversity of California San Diego, San Diego, CA, USA.
C J D IsaacsGeorgetown University, Washington, DC, USA.
C YauUniversity of California San Francisco, San Francisco, CA, USA.
L J EssermanUniversity of California San Francisco, San Francisco, CA, USA.
J C BougheyMayo Clinic, Rochester, MN, USA.
R A MukhtarUniversity of California San Francisco, San Francisco, CA, USA.

Funding

The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer OutcomesP01CA210961 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nola M. Hylton-Watson · 2017 to 2026
$22.9M
NCI NIH HHS P01 CA210961
6 · The paper itself

Abstract

backgroundMastectomy rates in women with breast cancer are higher in younger women than in older women. The impact of this more extensive surgery on overall survival (OS) and locoregional recurrence in younger women is unknown, especially after neoadjuvant systemic therapy (NST). This study evaluated surgical management and outcomes of patients aged ≤ 45 versus > 45 years enrolled in multicenter NST clinical trial, I-SPY2.0 (NCT01042379, PMID 37325931).

methodsWe conducted a secondary data analysis comparing locoregional treatment in patients aged ≤ 45 versus > 45 years with clinical or molecular high-risk clinical stage II-III breast cancer treated from April 2010 to June 2022. Multivariate Cox proportional hazards models were used to evaluate associations between type of breast surgery with OS and locoregional recurrence-free interval by age group and tumor receptor subtype.

resultsOf 1737 patients, 698 (40.2%) were aged ≤ 45 years. There were no significant differences in patient or tumor characteristics or residual cancer burden distribution between age groups. Although breast-conserving surgery was significantly less common in younger women (36.8% vs 48.5%, p < 0.001), surgery type was not associated with OS or locoregional recurrence-free interval for patients aged ≤ 45 years.

conclusionsGreater extent of breast surgery was not associated with improved outcomes in women aged ≤ 45 years. Choice of surgical procedure in the management of breast cancer is multifactorial, but young age alone does not warrant mastectomy following NST.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsMastectomyMastectomy, SegmentalNeoadjuvant TherapyNeoplasm Recurrence, LocalAdultAgedAge FactorsFemaleFollow-Up StudiesHumansMiddle AgedPrognosisSecondary Data AnalysisSurvival RateBreast cancerBreast conserving surgeryHigh riskMastectomySurgeryYoung women

Identifiers

PMID42545411
PMCPMC13630848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.